and Table  I SHR but not in WKY (Table I ). This similarity in effective doses suggests a similar basis for these effects, which may reflect differences in the vascular renin-angiotensin system between SHR and WKY. Antonaccio and Kerwin20) reported that the effects of captopril on blood pressure were not prominent in DOCA-salt hypertension with very low plasma and vascular renin activities. This finding also provides evidence that the hypotensive action of captopril depends upon its accessibility to the vascular renin-angiotensin system. In summary, the effects of captopril on norepinephrine release from the sympathetic nerve endings are consistent with the hypothesis that the antihypertensive action of captopril might be due to interference with the peripheral adrenergic neuro-effector mechanisms in the resistance vessels.
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